number of access : ?
number of downloads : ?
ID 115284
Author
Bando, Hiroshi Tokushima University|Japan Low Carbohydrate Diet Promotion Association KAKEN Search Researchers
Keywords
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors
Phlorizin
Antihypertensive Agents (AHA)
Cardiovascular Event
Blood Pressure
Content Type
Journal Article
Description
Sodium-glucose Cotransporter-2 Inhibitors (SGLT2i) has been in focus for the pharmacotherapy of diabetes. SGLT2i contributes to decreasing blood pressure (BP) to some degree. BP changes were analyzed in 4 well-known mega-studies. They are Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose (EMPA-REG OUTCOME) study, Canagliflozin cardioVascular Assessment Study (CANVAS), Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) and Dapagliflozin Effect on CardiovascuLAR Events (DECLARE)-TIMI 58. The ultimate goal of antihypertensive and hypoglycemic agents is not the achievement of target values, but the suppression of cardiovascular events. SGLT-2i show excellent strategy for event suppression and adjunct method for hypertension.
Journal Title
Asploro Journal of Biomedical and Clinical Case Reports
ISSN
25820370
Publisher
Asploro
Volume
3
Issue
3
Start Page
186
End Page
190
Published Date
2020-08-28
Rights
© 2020 Bando H. This is an open-access article distributed under the Creative Commons Attribution License(https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium provided the original work is properly cited.
DOI (Published Version)
URL ( Publisher's Version )
FullText File
language
eng
TextVersion
Publisher
departments
Medical Sciences